Micro-AbstractThere is a need to identify patients who may benefit from particular treatments. We investigated prognosis in 915 patients with mCRC from 2 phase III trials of panitumumab plus chemotherapy, based on Köhne category and BRAF status. Both Köhne category and BRAF status predicted outcomes in terms of PFS and OS, and panitumumab provided benefits over chemotherapy alone.
Clinical Colorectal Cancer – Elsevier
Published: Mar 1, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
It’s easy to organize your research with our built-in tools.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud